- Advance to first-line RAS-mutated mCRC follows the strong signal from new clinical and preclinical data, and agreement with FDA -
- First-line mCRC represents substantial increase in patient.
SAN DIEGO, July 24, 2023 /PRNewswire/ Cardiff Oncology, Inc. , a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies.
SAN DIEGO, June 20, 2023 /PRNewswire/ Cardiff Oncology, Inc. , a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies. | June 20, 2023